Efficacy of Pentoxifylline as Add on Therapy in COVID19 Patients
Status:
Not yet recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
With potential antiviral effects on severe acute respiratory syndrome (SARS) and as a
methyl-xanthine derived inhibitor of phosphodiesterase-4, pentoxifylline basically functions
as a hemorrheologic agent for a better circulation and oxygenation and exerts unique effects
on immune modulation, inflammation and oxidative stress. As the main regulator of cAMP
metabolism, posphodiesterase-4 plays a key role in proinflammatory and immune cells.
Pentoxifylline plays its anti-inflammatory role by reducing the production of proinflammatory
cytokines such as TNF-a, IL-1 and IL-6. Given its unique impacts on immune modulation,
homeostasis and fibrinolysis and its supportive effects on oxidative stress and organ
failure, pentoxifylline can constitute a multipurpose and generally-safe adjuvant therapy for
COVID-19 patients.